This article was originally published in The Gray Sheet
Executive SummaryProvider of genomic and related medical information agrees to acquire privately held Paracel, producer of advanced genomic and text analysis technologies, for stock valued at $283 mil. Pasadena, California-based Paracel's products include GeneMatcher, "the world's fastest sequence comparison supercomputer," high-throughput sequence analysis and annotation software tools, and the TextFinder text search supercomputer. "We believe Paracel's advanced supercomputing technology and expertise is synergistic with Celera's comprehensive genomics content enabling us to create the premier genomic discovery portal," Celera says
You may also be interested in...
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.